Johnson & Johnson / Janssen clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-05
What changed in the last 30 days
62 trials changed in the last 30 days: 0 stopped, 11 with notable changes, 51 with minor changes only.
- Notable: cAMeLot-1 · Bleximenib · Acute Leukemia Primary completion pushed from Feb 26, 2027 to Dec 29, 2028
- Notable: GreatPFA · Varipulse Catheter · Paroxysmal Atrial Fibrillation Under Optimized Sedation Recruitment opened
- Minor: SPIREA · Nipocalimab · Active Idiopathic Inflammatory Myopathies Trial completed
- Notable: JNJ-101556143 With Best Supportive Care · Metastatic Prostate Cancer Recruitment opened
- Notable: READY-BREATHE · JNJ-95597528 · Inadequately Controlled Moderate to Severe Asthma Recruitment opened
- Notable: Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy Results posted: Nov 3, 2026
- Notable: JNJ-98768111 · Advanced Prostate Cancer Enrollment increased: 100 → 160 participants
- Minor: ICONIC-PsA 2 · Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive · Active Psoriatic Arthritis Enrollment closed, study ongoing
- Minor: ICONIC-UC · Protocol of Icotrokinra Therapy in Adult and Adolescent · Moderately to Severely Active Ulcerative Colitis Enrollment closed, study ongoing
- Minor: VELOTA · JNJ-88545223 · Active Psoriatic Arthritis Enrollment closed, study ongoing
- Minor: Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies Trial completed
- Minor: TAR-210 · Erdafitinib Intravesical Delivery System · Bladder Cancer Trial completed
- Minor: JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms Trial completed
- Minor: MoMMent · Real-Life Current Standards of Care · Relapsed and/or Refractory Multiple Myeloma Enrollment closed, study ongoing
- Minor: Ped IBD Claims · Database Study of Disease, Treatment Patterns and Healthcare Use · Inflammatory Bowel Diseases in Korea Enrollment closed, study ongoing
- Minor: Approved Contact Lenses (CR-6657) Enrollment closed, study ongoing
- Minor: Teclistamab in Indian · Relapsed and Refractory Multiple Myeloma Primary completion pushed from Nov 3, 2026 to Feb 12, 2027
- Minor: QOLIBRI · Benefits of Individual Physical Activity Intervention on Health-related Quality of Life · Chronic Lymphocytic Leukemia Primary completion pushed from Sep 30, 2026 to Oct 30, 2026
- Minor: OrigAMI-5 · Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone · Recurrent/Metastatic Head and Neck Cancer Enrollment increased: 500 → 600 participants
- Minor: JNJ-95804306 for Relapsed or Refractory Hematological Malignancies Enrollment reduced: 360 → 320 participants
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New trial filings, last 30 days
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-11-04 | NCT07915232 A Study to Assess Pregnancy, Neonatal and Infant Outcomes in Participants Exposed to… | Not Yet Recruiting | |
| 2026-10-30 | NCT07906717 A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic… | Phase 3 | Recruiting |
| 2026-10-29 | NCT07903272 A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab… | Phase 3 | Not Yet Recruiting |
| 2026-10-22 | NCT07890285 A Study of Opsynvi in Adults Participants With Pulmonary Arterial Hypertension in Korea | Not Yet Recruiting |
Active trials by phase
| Phase 1 | 45 | |
| Phase 1/2 | 12 | |
| Phase 2 | 28 | |
| Phase 2/3 | 7 | |
| Phase 3 | 73 | |
| Phase 4 | 6 |
Not charted: 35 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Disease areas by active trials, top 10 of 33
Multiple Myeloma (33) · Prostate Cancer (23) · Crohn's Disease (22) · Psoriasis (22) · Ulcerative Colitis (20) · Lung Cancer (17) · Non-Small Cell Lung Cancer (NSCLC) (17) · Psoriatic Arthritis (13) · Bladder Cancer (12) · Leukemia (11)
Get alerts when Johnson & Johnson / Janssen's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.